SCHD Schwab US Dividend Equity ETF
Profitability Metrics
Valuation Metrics
Growth & Cash Flow
Price Change
Top 10 Holdings
| Stock Ticker | Weight |
|---|---|
| CVX | 4.58% |
| COP | 4.29% |
| MRK | 4.12% |
| VZ | 4.04% |
| KO | 4.01% |
| TXN | 3.95% |
| PEP | 3.90% |
| AMGN | 3.82% |
| UNH | 3.82% |
| PG | 3.76% |
ETF Analysis
Fund Overview
Schwab US Dividend Equity ETF (SCHD) currently reports 99 stock positions (subject to change), placing it in the balanced in breadth range by holdings breadth. The top line-up is CVX (4.58%), COP (4.29%), MRK (4.12%), with CVX as the largest single weight at 4.58%. Together, the top three holdings account for 12.99%, which reflects a construction where the top positions carry meaningful but not outsized influence on aggregate returns. In aggregate, the construction reflects a balance between directional conviction and the diversification benefits that come from a broader holding set.
Profitability & Capital Efficiency
On the question of capital productivity, ROIC is 18.13%, WACC is 7.03%, and the economic spread is 11.10%. On balance, the economic spread is positive and meaningful, suggesting the underlying holdings are building rather than eroding intrinsic value. Supporting metrics show ROE at 34.87% and ROA at 8.77%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a portfolio with credible compounding capacity if current operating execution persists.
Valuation
On a multiple basis, the portfolio trades at trailing P/E of 18.25, forward P/E of 15.09, PEG of 2.40. Forward P/E is broadly in line with trailing, suggesting analysts are not projecting a material change in profitability over the coming year. At this PEG level, valuation is defensible given the growth outlook, though there is limited margin of safety against estimate disappointments. The portfolio carries an aggregate current ratio of 1.42, pointing to constrained near-term balance sheet coverage. The valuation setup is broadly consistent with a market that is pricing growth without being reckless about it — a balanced but not cautious stance.
Margins & Cash Generation
The margin stack reads as follows: gross margin sits at 49.49%, operating margin at 22.70%, and free cash flow margin at 16.87%. The gross margin reading points to holdings with solid but not outsized pricing power relative to direct costs. The portfolio's operating margins are solid, pointing to holdings where overhead management is a relative strength. FCF margins are constructive here, reflecting holdings that generate cash reliably after reinvestment requirements. The margin profile is a mixed read — some holdings are clearly well-run, but the aggregate numbers point to a basket that is not uniformly high-quality.
Growth & Forward Outlook
The forward view combines two signals: the estimated 12-month price change of 12.80%, where analyst assumptions support a moderate upside case if execution remains steady, while TTM revenue growth of 6.14% suggesting the portfolio's holdings are growing revenues at a measured, sustainable pace. The projected 12-month EPS growth rate of 20.9% is a standout component of the forward case — meaningful earnings expansion at this scale typically warrants attention from growth-oriented investors. One metric reflects operational reality, the other market expectation — both are useful inputs, but neither should be read in isolation. The interaction between revenue execution and analyst repricing will ultimately determine how closely realized returns track current expectations. The estimated 12-month price change is a weighted composite of analyst price target estimates adjusted by each holding's ETF weight, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.
Conclusion
BuyThe overall evidence base is constructive, with more signals pointing up than down and no obvious structural impairment to the forward case.
The views expressed above are derived from quantitative data only and should not be relied upon as financial advice. Investment decisions should be based on your own research and risk tolerance.